Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting
April 12, 2018 17:09 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced it will make six data presentations at the 70th Annual Meeting of the American...
Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
April 10, 2018 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and...
Epilepsy Foundation Awards $200,000 at ‘Shark Tank’ Competition for Innovative Products that Aim to Improve Epilepsy Treatment and Care
March 05, 2018 08:00 ET
|
Epilepsy Foundation
LANDOVER, Md., March 05, 2018 (GLOBE NEWSWIRE) -- The Epilepsy Foundation announced the winners of the 2018 Shark Tank competition for innovative ideas in epilepsy and seizure treatment and care on...
Stopping Epilepsy Before It Starts? CURE Researcher Identifies a Possible Biomarker
February 06, 2018 09:50 ET
|
About Citizens United for Research in Epilepsy (CURE)
Chicago, Feb. 06, 2018 (GLOBE NEWSWIRE) -- New research, funded by Citizens United for Research in Epilepsy (CURE), has discovered a ‘smoking gun’ biomarker that could result in treatments that stop...
Earth Science Tech, Inc. President Commits to Donating 50,000 of his Personal Shares to Become the First Contributor to Earth Science Foundation
January 18, 2018 08:00 ET
|
Earth Science Tech, Inc.
Doral, FL, Jan. 18, 2018 (GLOBE NEWSWIRE) --
Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST" or the “Company"), an innovative biotech company that operates in the fields of cannabinoid...
Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
January 03, 2018 16:30 ET
|
Zynerba Pharmaceuticals, Inc.
- Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30...
Dr. Paul Carney Joins Biotica Pharmaceuticals as Neurologist Consultant and Scientific Advisor
January 03, 2018 08:00 ET
|
Biotica Pharmaceuticals Inc.
Sarasota, FL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Biotica Pharmaceuticals Inc. (Biotica), an early-stage biotech engaging in the discovery, development, and commercialization of cannabinoid-based...
Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
December 03, 2017 12:01 ET
|
Zynerba Pharmaceuticals, Inc.
- Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study – - Data Help Clarify Protocol Design for...
Epilepsy Foundation Champions Need for Increased Public Knowledge, Timely Diagnosis and Proper Treatment for 3.4 Million People Living with Active Seizures in the United States
November 06, 2017 09:00 ET
|
Epilepsy Foundation
CDC: ‘More People Live with Epilepsy than Ever Before’ Under-Diagnosis of Epilepsy, Poor Seizure Management are Common and May Be Devastating or Fatal; Specialty Care, Found at Comprehensive...
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
November 02, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30,...